These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 18848313)

  • 1. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
    van Doorn PA; Ruts L; Jacobs BC
    Lancet Neurol; 2008 Oct; 7(10):939-50. PubMed ID: 18848313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
    Verma R; Chaudhari TS; Raut TP; Garg RK
    J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guillain-Barre syndrome: etiology and pathogenesis].
    Avila-Funes JA; Mariona-Montero VA; Melano-Carranza E
    Rev Invest Clin; 2002; 54(4):357-63. PubMed ID: 12415961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for Guillain-Barré syndrome.
    Walgaard C; Jacobs BC; van Doorn PA
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):105-20. PubMed ID: 21352072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Guillain-Barré syndrome.
    Fujimura H
    Handb Clin Neurol; 2013; 115():383-402. PubMed ID: 23931791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guillian-Barre syndrome.
    Talukder RK; Sutradhar SR; Rahman KM; Uddin MJ; Akhter H
    Mymensingh Med J; 2011 Oct; 20(4):748-56. PubMed ID: 22081202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis.
    Yuki N
    Jpn J Infect Dis; 1999 Jun; 52(3):99-105. PubMed ID: 10507987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies.
    Prendergast MM; Moran AP
    J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in management of Guillain-Barré syndrome.
    Doets AY; Jacobs BC; van Doorn PA
    Curr Opin Neurol; 2018 Oct; 31(5):541-550. PubMed ID: 30074496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré syndrome: epidemiology, pathophysiology and management.
    Kuwabara S
    Drugs; 2004; 64(6):597-610. PubMed ID: 15018590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
    França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Guillain-Barré syndrome and CIDP.
    van Doorn PA
    J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome].
    Orlikowski D; Quijano-Roy S; Sivadon-Tardy V; Raphael JC; Gaillard JL
    Arch Pediatr; 2006 Dec; 13(12):1561-5. PubMed ID: 17030119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.